InsiderSource
CBIO

CRESCENT BIOPHARMA, INC.

SEC CIK 1253689
$17.95 +88.7% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
14
Most recent
Advertisement

At a glance

Insiders at CBIO have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Fairmount Funds Management Llc, CBIO's 10% owner, spent $18.24M of their own money on 1.36M shares at $13, growing their stake 98%.

Most active filer: Invus Public Equities, L.p., with 4 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for CBIO, newest first
View on SEC EDGAR ↗
Advertisement
CBIO
CRESCENT BIOPHARMA, INC.
Buy Fairmount Funds Management LLC · Director, 10% Owner · Open-market purchase · filed Dec 8, 2025 ΔOwn +98%

Fairmount Funds Management Llc, CBIO's 10% owner, spent $18.24M of their own money on 1.36M shares at $13, growing their stake 98%.

+$18.24M
1.36M sh @ $13
GLYC
GLYCOMIMETICS INC
Sell Invus Public Equities, L.P. · 10% Owner · Open-market sale · filed Aug 9, 2024 ΔOwn −4.0%

Invus Public Equities, L.p. sold $50K of GLYC, trimming their stake 4%.

−$50K
260,873 sh @ $0
GLYC
GLYCOMIMETICS INC
Sell Invus Public Equities, L.P. · 10% Owner · Open-market sale · filed Aug 9, 2024 ΔOwn −0.9%

Invus Public Equities, L.p. sold $11.2K of GLYC, trimming their stake 1%.

−$11.2K
61,488 sh @ $0
GLYC
GLYCOMIMETICS INC
Sell Invus Public Equities, L.P. · 10% Owner · Open-market sale · filed Aug 7, 2024 ΔOwn −0.8%

Invus Public Equities, L.p. sold $10.2K of GLYC, trimming their stake 1%.

−$10.2K
55,732 sh @ $0
GLYC
GLYCOMIMETICS INC
Sell Invus Public Equities, L.P. · 10% Owner · Open-market sale · filed Aug 7, 2024 ΔOwn −2.4%

Invus Public Equities, L.p. sold $31K of GLYC, trimming their stake 2%.

−$31K
164,523 sh @ $0
Advertisement

About CBIO insider activity

This page tracks every recent Form 4 filed for CRESCENT BIOPHARMA, INC. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is CBIO insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for CRESCENT BIOPHARMA, INC. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.